Research on Chemical Intermediates p. 2433 - 2467 (2021)
Update date:2022-08-05
Topics:
Devi
Sharma
Kumar
Jindal
Dutta
Kumar
Abstract: A series of transition metal (II) complexes with general formula [M(L1?4)2(H2O)2] (where M = Co(II), Ni(II), Cu(II) and Zn(II)) was synthesized by the reaction of metal(II) acetates with hydrazones [HL1–HL4] obtained from condensation of tetralone with hydrazide derivatives. The characterization of synthesized compounds (1–20) was done by using elemental analysis, different spectral studies (UV–Vis, 1H NMR, 13C NMR, FT-IR, mass, ESR and fluorescence), magnetic susceptibility, molar conductance measurement and thermal (DTA, TGA and DTG) analysis. The characterization results suggested the bidentate nature of the hydrazones, which chelate with the metal ion via nitrogen of (C=N) group and deprotonated carbonyl oxygen in the enolized form, resulting in stable, non-volatile octahedral complexes. The antimicrobial potential of the compounds was evaluated against four bacterial, i.e. (S. aureus, B. subtilis, P. aeruginosa and E. coli), and two fungal species, i.e. (A. niger and C. albicans), by a serial dilution method with complexes 15 and 16 as most active compounds against microbes. All the compounds were also tested for its cytotoxicity (in vitro) against three human cancer cell lines (A549, HeLa and MCF-7) and one normal cell line (L6) by the MTT assay, which focussed on an increased activity of compounds 7 and 15 towards A549, MCF-7 and HeLa cancer cell line with IC50 values ranging from 10.76 to 16.42?μg/mL, and compounds were found to be non-toxic towards L6 cell line as compared to the standard drug doxorubicin. The results demonstrated that complexation enhanced the biological activity of compounds. Graphic abstract: The synthesized compounds (1–20) were screened for antitumor activities against A549, MCF7, Hela cancer cell lines. Copper complex (7) and (15) was found to be the most active antitumor agent and less toxic against L6—Rat myoblast normal cell line than standard doxorubicin.[Figure not available: see fulltext.].
View MoreContact:86+21-56421993
Address:3F,BUILDING 10,NO.2889 JINKE ROAD, SHANGHAI.
Jinan Yijialian Economic and Trade Development Co., Ltd.
Contact:+86 0531-66729596
Address:jinan
Shanghai Mokai Pharmaceutical Co.,Ltd
Contact:021-60257269
Address:Rm506,No.915,Zhenbei Road,Shanghai,200333,China
Feis International Trade Co,. Ltd
Contact:13961823444-18235944442
Address:Wuxi jiangsu
Nanjing Vincero International Trading Co.,Ltd
Contact:8618936897229
Address:NO.68, ZhuShan Road, JiangNing WanDa Plaza, Building E Room 1703
Doi:10.1021/ja00782a025
(1973)Doi:10.1248/cpb.36.122
(1988)Doi:10.1021/ol901086f
(2009)Doi:10.1055/s-1988-27601
(1988)Doi:10.1016/j.tetlet.2009.03.024
(2009)Doi:10.1016/0040-4039(88)85248-1
(1988)